Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_017739.4(POMGNT1):āc.1867A>Gā(p.Met623Val) variant causes a missense change. The variant allele was found at a frequency of 0.99 in 1,613,718 control chromosomes in the GnomAD database, including 792,524 homozygotes. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M623L) has been classified as Uncertain significance.
POMGNT1 (HGNC:19139): (protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-)) This gene encodes a type II transmembrane protein that resides in the Golgi apparatus. It participates in O-mannosyl glycosylation and is specific for alpha linked terminal mannose. Mutations in this gene may be associated with muscle-eye-brain disease and several congenital muscular dystrophies. Alternatively spliced transcript variants that encode different protein isoforms have been described. [provided by RefSeq, Feb 2014]
TSPAN1 (HGNC:20657): (tetraspanin 1) The protein encoded by this gene is a member of the transmembrane 4 superfamily, also known as the tetraspanin family. Most of these members are cell-surface proteins that are characterized by the presence of four hydrophobic domains. The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility. [provided by RefSeq, Jul 2008]
Computational evidence support a benign effect (MetaRNN=1.4922764E-6).
BP6
Variant 1-46189486-T-C is Benign according to our data. Variant chr1-46189486-T-C is described in ClinVar as [Benign]. Clinvar id is 167524.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.993 is higher than 0.05.
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
-
- -
Benign, criteria provided, single submitter
clinical testing
Eurofins Ntd Llc (ga)
Mar 10, 2015
- -
Benign, criteria provided, single submitter
clinical testing
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Nov 26, 2014
This is a RefSeq error. The reference base (c.1867A) is the minor allele. This a llele (A) has been identified in 17% (759/4406) of African American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs6710212) and thus meets criteria to be classified as benign. -
Benign, no assertion criteria provided
clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
-
- -
Muscle eye brain disease Benign:2
Benign, criteria provided, single submitter
clinical testing
Mendelics
May 28, 2019
- -
Benign, no assertion criteria provided
clinical testing
Natera, Inc.
Nov 16, 2019
- -
Retinitis pigmentosa 76 Benign:1
Benign, criteria provided, single submitter
clinical testing
Genome-Nilou Lab
Oct 25, 2021
- -
Autosomal recessive limb-girdle muscular dystrophy type 2O Benign:1
Benign, criteria provided, single submitter
clinical testing
Genome-Nilou Lab
Oct 25, 2021
- -
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3;C3150417:Autosomal recessive limb-girdle muscular dystrophy type 2O Benign:1
Benign, criteria provided, single submitter
clinical testing
Labcorp Genetics (formerly Invitae), Labcorp
Feb 01, 2024
- -
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3 Benign:1
Benign, criteria provided, single submitter
clinical testing
Genome-Nilou Lab
Oct 25, 2021
- -
not provided Benign:1
Benign, criteria provided, single submitter
not provided
Breakthrough Genomics, Breakthrough Genomics
-
- -
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3 Benign:1